Precipio, Inc. (PRPO)

Precipio, Inc.'s stock price has experienced significant events and volatility over the past six months, with a substantial increase of 303.79% to 319.40% over the past year. In Q3 2025, Precipio announced strong financial results, with revenue rising 29.9% year-over-year and a 19.7% sequential increase. The company identified unauthorized access to isolated storage but stated there was no operational impact. Precipio showcased its BCR::ABL1 panel at the 2025 American Society of Hematology (ASH) Meeting. Precipio terminated its At-The-Market (ATM) agreement with Alliance Global. The company reported achieving positive Adjusted EBITDA of $0.4M and a cash flow increase of $0.3M in Q4 2024. Precipio was impacted by the Change Healthcare hacking, which caused a freeze on cash inflow from its pathology services division.

Information regarding the demand seasonality for Precipio, Inc.'s products and services is not explicitly detailed in the provided search results. The available data on seasonality refers to the historical stock price performance, indicating that May has the highest probability of a positive stock return (75.00%), while December has the lowest (0.00%). Q1 can present challenges due to insurance deductible renewals, which could imply some seasonality in pathology business revenues and cash receipts.

Precipio, Inc. is a healthcare biotechnology company specializing in cancer diagnostics, operating within the Biotechnology: Laboratory Analytical Instruments and Medical Diagnostic & Testing Equipment industries. The company focuses on developing solutions to mitigate cancer misdiagnoses through diagnostic products, reagents, and services. Its major products and technologies include IV-Cell, a proprietary cell culture media; HemeScreen, a suite of genetic diagnostic panels; ICP (ICE COLD-PCR); and SmartPath and SmartGen diagnostic services. Precipio also offers biomarker testing and clinical project services to bio-pharma customers.

Precipio, Inc. primarily provides its cancer diagnostic products, reagents, and services in the United States. The company operates Clinical Laboratory Improvement Amendments (CLIA) laboratories in New Haven, Connecticut, and Omaha, Nebraska, which provide blood cancer diagnostics to oncologists nationwide. Precipio aims to commercialize its technologies as proprietary products that serve the global laboratory community and further scales its reach to eradicate misdiagnosis through a network of global distribution partners.

Precipio's brand reputation in the past year appears to be generally positive, driven by strong financial performance and its mission in cancer diagnostics. The company's Q3 2025 earnings report highlighted significant revenue growth, improved profitability, and positive cash flow. The announcement of unauthorized access to isolated storage on December 4, 2025, did not have any operational impact, which likely mitigated any significant negative reputational damage. The company's participation in events like the 2025 ASH Meeting also contributes to its scientific and industry standing.

Precipio, Inc. has a mixed ownership structure, with institutional shareholders, insiders, and retail investors. Precipio insiders own a significant portion of the company, approximately 1,388.78% according to one source, and 11.09% according to another. Randal J. Kirk is the largest individual shareholder, owning 10.83 million shares, representing 617.94% of the company. Institutional shareholders hold approximately 18.06% to 15.25% of the company's stock. Major institutional owners include AMH Equity Ltd, Topline Capital Management, LLC, and BlackRock, Inc.